CytoDyn, Inc. (OTCQB: CYDY) is focused on developing new therapies that provide flexibility and freedom to people across the globe who are living with HIV. The company’s lead product, PRO 140, belongs to a new class of HIV/AIDS therapeutics that protects healthy cells from viral infection. PRO 140 has several potential benefits including less frequent dosing and minimal side effects that distinguish it from currently used HIV treatments. For more information, visit the company’s website at www.cytodyn.com.
CytoDyn (CYDY) Presents at Rodman & Renshaw Conference
Previous Article
Next Article
Search Articles
Latest Articles
- FAVO Capital Inc. (FAVO): When Private Credit Meets Real Estate Collateralization
- AI and the Copper Conundrum: How Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Fits into the Supply Equation
- Silvercorp Metals Inc. (NYSE-A/TSX: SVM) El Domo Environmental License Upheld as Ecuador’s Constitutional Court Dismisses Final Challenge
- NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative
- MissionIRNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Closes $6.9 Million Public Offering Including Full Over-Allotment Option